244 related articles for article (PubMed ID: 8355512)
1. Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic effects of chemotherapy and BMT.
Kiyoi H; Naoe T; Yamauchi T; Fukatani H; Kubo K; Kojima S; Ohno R
Leuk Res; 1993 Aug; 17(8):677-84. PubMed ID: 8355512
[TBL] [Abstract][Full Text] [Related]
2. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
[TBL] [Abstract][Full Text] [Related]
3. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
[TBL] [Abstract][Full Text] [Related]
5. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
7. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Brisco J; Hughes E; Neoh SH; Sykes PJ; Bradstock K; Enno A; Szer J; McCaul K; Morley AA
Blood; 1996 Jun; 87(12):5251-6. PubMed ID: 8652840
[TBL] [Abstract][Full Text] [Related]
8. Detection of minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view.
Miyamura K; Takeo T; Kataoka T; Tahara T; Tanimoto M; Saito H
Leuk Lymphoma; 1993 Oct; 11(3-4):181-9. PubMed ID: 8260893
[TBL] [Abstract][Full Text] [Related]
9. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
10. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia.
Fière D; Lepage E; Sebban C; Boucheix C; Gisselbrecht C; Vernant JP; Varet B; Broustet A; Cahn JY; Rigal-Huguet F
J Clin Oncol; 1993 Oct; 11(10):1990-2001. PubMed ID: 8410124
[TBL] [Abstract][Full Text] [Related]
11. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.
Uckun FM; Kersey JH; Vallera DA; Ledbetter JA; Weisdorf D; Myers DE; Haake R; Ramsay NK
Blood; 1990 Nov; 76(9):1723-33. PubMed ID: 2224122
[TBL] [Abstract][Full Text] [Related]
12. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
13. Profile of immunoglobulin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia.
Greenberg SJ; Choi Y; Ballow M; Du TL; Ward PM; Rickert MH; Frankel S; Bernstein SH; Brecher ML
J Leukoc Biol; 1995 Jun; 57(6):856-64. PubMed ID: 7790768
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.
Mortuza FY; Papaioannou M; Moreira IM; Coyle LA; Gameiro P; Gandini D; Prentice HG; Goldstone A; Hoffbrand AV; Foroni L
J Clin Oncol; 2002 Feb; 20(4):1094-104. PubMed ID: 11844835
[TBL] [Abstract][Full Text] [Related]
15. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
[TBL] [Abstract][Full Text] [Related]
16. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
Bordigoni P; Esperou H; Souillet G; Pico J; Michel G; Lacour B; Reiffers J; Sadoun A; Rohrlich P; Jouet JP; Milpied N; Lutz P; Plouvier E; Cornu G; Vannier JP; Gandemer V; Rubie H; Gratecos N; Leverger G; Stephan JL; Boutard P; Vernant JP
Br J Haematol; 1998 Aug; 102(3):656-65. PubMed ID: 9722290
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
Blaise D; Gaspard MH; Stoppa AM; Michel G; Gastaut JA; Lepeu G; Tubiana N; Blanc AP; Rossi JF; Novakovitch G
Bone Marrow Transplant; 1990 Jan; 5(1):7-12. PubMed ID: 2404531
[TBL] [Abstract][Full Text] [Related]
18. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation.
Miyamura K; Tanimoto M; Morishima Y; Horibe K; Yamamoto K; Akatsuka M; Kodera Y; Kojima S; Matsuyama K; Hirabayashi N
Blood; 1992 Mar; 79(5):1366-70. PubMed ID: 1371420
[TBL] [Abstract][Full Text] [Related]
19. Repetitious appearance and disappearance of different kinds of clonal cytogenetic abnormalities after allogeneic bone marrow transplantation.
Lin YW; Hamahata K; Watanabe K; Adachi S; Akiyama Y; Kubota M; Nakahata T
Int J Hematol; 2001 Jul; 74(1):86-9. PubMed ID: 11530811
[TBL] [Abstract][Full Text] [Related]
20. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
